Hemogenyx Pharmaceuticals Plc
HEMO.L · LSE
| Reporting period ended | 12/31/2024 FY 2024 | 12/31/2023 FY 2023 | 12/31/2022 FY 2022 | 12/31/2021 FY 2021 |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.08 | 0.08 | -0.09 |
| FCF Yield | -30.89% | -23.96% | -25.63% | -23.68% |
| EV / EBITDA | -3.36 | -4.82 | -4.07 | -3.23 |
| Quality | ||||
| ROIC | -146.83% | -92.64% | 57.20% | -33.01% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.73 | 0.91 | 0.73 | 0.51 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 33.63% | -86.34% | 3.07% | -74.76% |
| Safety | ||||
| Net Debt / EBITDA | -0.52 | -0.30 | -0.26 | 2.86 |
| Interest Coverage | -21.09 | -17.59 | 121,137.82 | -1.04 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -390.12 | -170.55 | -52.56 | -380.68 |